Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organogenesis Holdings (ORGO) Change in Inventory (2018 - 2025)

Historic Change in Inventory for Organogenesis Holdings (ORGO) over the last 8 years, with Q3 2025 value amounting to -$938000.0.

  • Organogenesis Holdings' Change in Inventory fell 12508.02% to -$938000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $15.4 million, marking a year-over-year increase of 13871.42%. This contributed to the annual value of $6.2 million for FY2024, which is 2414.72% down from last year.
  • As of Q3 2025, Organogenesis Holdings' Change in Inventory stood at -$938000.0, which was down 12508.02% from $7.2 million recorded in Q2 2025.
  • In the past 5 years, Organogenesis Holdings' Change in Inventory registered a high of $8.7 million during Q1 2025, and its lowest value of -$2.7 million during Q2 2024.
  • For the 5-year period, Organogenesis Holdings' Change in Inventory averaged around $2.5 million, with its median value being $2.2 million (2023).
  • Its Change in Inventory has fluctuated over the past 5 years, first skyrocketed by 280375.0% in 2023, then crashed by 24139.21% in 2024.
  • Over the past 5 years, Organogenesis Holdings' Change in Inventory (Quarter) stood at -$439000.0 in 2021, then surged by 584.74% to $2.1 million in 2022, then tumbled by 66.82% to $706000.0 in 2023, then crashed by 35.55% to $455000.0 in 2024, then plummeted by 306.15% to -$938000.0 in 2025.
  • Its Change in Inventory stands at -$938000.0 for Q3 2025, versus $7.2 million for Q2 2025 and $8.7 million for Q1 2025.